Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that management will present and host one-on-one meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET. A live webcast and replay will be available under the News & Events tab in the Investors section of the company's website.
The presentation offers investors and industry stakeholders an opportunity to hear directly from Tonix leadership about the company's progress and strategic priorities. Tonix focuses on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace SymTouch and Tosymra.
Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In addition, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company notes that its product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The conference appearance matters because it gives Tonix a platform to engage with investors and potential partners at a time when the company is transitioning from a development-stage focus to a commercial-stage operation. With TONMYA approved and marketed, Tonix is seeking to demonstrate that it can execute on commercialization while continuing to advance its clinical pipeline. For readers following the biopharmaceutical sector, the presentation may provide updates on launch metrics, pipeline timelines, and capital allocation priorities.
For those interested in the full details of the announcement, the complete press release is available at https://ibn.fm/f7udM. Additional news and updates about Tonix Pharmaceuticals can be found in the company's newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, offering services such as editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The full terms of use and disclaimers for InvestorWire content are available at https://www.InvestorWire.com/Disclaimer.
